Henry Schein, Inc. (NASDAQ:HSIC) Director Paul Brons sold 1,758 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $70.96, for a total transaction of $124,747.68. Following the completion of the sale, the director now directly owns 17,582 shares of the company’s stock, valued at approximately $1,247,618.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
HSIC traded down $0.12 during trading hours on Friday, reaching $71.27. 52,067 shares of the stock traded hands, compared to its average volume of 1,334,818. The firm has a market cap of $10.68 billion, a price-to-earnings ratio of 17.24, a PEG ratio of 2.51 and a beta of 0.82. Henry Schein, Inc. has a fifty-two week low of $56.58 and a fifty-two week high of $91.35. The company has a current ratio of 1.65, a quick ratio of 0.93 and a debt-to-equity ratio of 0.34.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.04. The business had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.36 billion. Henry Schein had a net margin of 4.10% and a return on equity of 18.35%. The business’s revenue was up 3.8% on a year-over-year basis. During the same period last year, the business earned $0.95 EPS. On average, analysts forecast that Henry Schein, Inc. will post 3.45 earnings per share for the current fiscal year.
Several equities research analysts have recently issued reports on HSIC shares. Guggenheim started coverage on shares of Henry Schein in a research report on Wednesday, April 17th. They issued a “buy” rating and a $72.00 price objective for the company. Craig Hallum dropped their price objective on shares of Henry Schein from $96.00 to $72.00 and set a “buy” rating for the company in a research report on Tuesday, February 19th. Royal Bank of Canada dropped their price objective on shares of Henry Schein to $62.00 and set a “sector perform” rating for the company in a research report on Thursday, February 21st. Zacks Investment Research lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a research report on Tuesday, February 26th. Finally, Barrington Research reissued a “buy” rating and issued a $72.00 price objective on shares of Henry Schein in a research report on Thursday, February 21st. Seven analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company’s stock. Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $74.27.
TRADEMARK VIOLATION WARNING: This piece was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2019/06/14/insider-selling-henry-schein-inc-nasdaqhsic-director-sells-1758-shares-of-stock.html.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also: Price to Earnings Ratio (PE)
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.